273 related articles for article (PubMed ID: 18932182)
1. TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival.
Perner S; Wagner PL; Soltermann A; LaFargue C; Tischler V; Weir BA; Weder W; Meyerson M; Giordano TJ; Moch H; Rubin MA
J Pathol; 2009 Jan; 217(1):65-72. PubMed ID: 18932182
[TBL] [Abstract][Full Text] [Related]
2. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.
Dacic S; Flanagan M; Cieply K; Ramalingam S; Luketich J; Belani C; Yousem SA
Am J Clin Pathol; 2006 Jun; 125(6):860-5. PubMed ID: 16690485
[TBL] [Abstract][Full Text] [Related]
3. Significance of p63 amplification and overexpression in lung cancer development and prognosis.
Massion PP; Taflan PM; Jamshedur Rahman SM; Yildiz P; Shyr Y; Edgerton ME; Westfall MD; Roberts JR; Pietenpol JA; Carbone DP; Gonzalez AL
Cancer Res; 2003 Nov; 63(21):7113-21. PubMed ID: 14612504
[TBL] [Abstract][Full Text] [Related]
4. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma.
Anagnostou VK; Syrigos KN; Bepler G; Homer RJ; Rimm DL
J Clin Oncol; 2009 Jan; 27(2):271-8. PubMed ID: 19064983
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of Yes-associated protein is correlated with expression of cell cycle markers and pathologic TNM staging in non-small-cell lung carcinoma.
Kim JM; Kang DW; Long LZ; Huang SM; Yeo MK; Yi ES; Kim KH
Hum Pathol; 2011 Mar; 42(3):315-23. PubMed ID: 21190720
[TBL] [Abstract][Full Text] [Related]
6. Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer.
Ishikawa S; Nakagawa T; Miyahara R; Kawano Y; Takenaka K; Yanagihara K; Otake Y; Katakura H; Wada H; Tanaka F
Clin Cancer Res; 2005 Feb; 11(3):1198-202. PubMed ID: 15709189
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma.
Puglisi F; Barbone F; Damante G; Bruckbauer M; Di Lauro V; Beltrami CA; Di Loreto C
Mod Pathol; 1999 Mar; 12(3):318-24. PubMed ID: 10102618
[TBL] [Abstract][Full Text] [Related]
8. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
Angulo B; Suarez-Gauthier A; Lopez-Rios F; Medina PP; Conde E; Tang M; Soler G; Lopez-Encuentra A; Cigudosa JC; Sanchez-Cespedes M
J Pathol; 2008 Feb; 214(3):347-56. PubMed ID: 17992665
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of calbindin-D28k expression in lung cancer: analysis of 452 cases.
Castro CY; Stephenson M; Gondo MM; Medeiros LJ; Cagle PT
Mod Pathol; 2000 Jul; 13(7):808-13. PubMed ID: 10912942
[TBL] [Abstract][Full Text] [Related]
10. SOX2 amplification is a common event in squamous cell carcinomas of different organ sites.
Maier S; Wilbertz T; Braun M; Scheble V; Reischl M; Mikut R; Menon R; Nikolov P; Petersen K; Beschorner C; Moch H; Kakies C; Protzel C; Bauer J; Soltermann A; Fend F; Staebler A; Lengerke C; Perner S
Hum Pathol; 2011 Aug; 42(8):1078-88. PubMed ID: 21334718
[TBL] [Abstract][Full Text] [Related]
11. CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung.
Kwon MS; Shin SH; Yim SH; Lee KY; Kang HM; Kim TM; Chung YJ
Lung Cancer; 2007 Jul; 57(1):46-53. PubMed ID: 17350713
[TBL] [Abstract][Full Text] [Related]
12. Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer.
Apostolopoulou K; Pateras IS; Evangelou K; Tsantoulis PK; Liontos M; Kittas C; Tiniakos DG; Kotsinas A; Cordon-Cardo C; Gorgoulis VG
J Pathol; 2007 Nov; 213(3):294-302. PubMed ID: 17907153
[TBL] [Abstract][Full Text] [Related]
13. Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung.
O-charoenrat P; Rusch V; Talbot SG; Sarkaria I; Viale A; Socci N; Ngai I; Rao P; Singh B
Clin Cancer Res; 2004 Sep; 10(17):5792-803. PubMed ID: 15355908
[TBL] [Abstract][Full Text] [Related]
14. Sex-specific survival advantage with parathyroid hormone-related protein in non-small cell lung carcinoma patients.
Hastings RH; Laux AM; Casillas A; Xu R; Lukas Z; Ernstrom K; Deftos LJ
Clin Cancer Res; 2006 Jan; 12(2):499-506. PubMed ID: 16428492
[TBL] [Abstract][Full Text] [Related]
15. Estrogen-receptor-related protein p29 in primary nonsmall cell lung carcinoma: pathologic and prognostic correlations.
Vargas SO; Leslie KO; Vacek PM; Socinski MA; Weaver DL
Cancer; 1998 Apr; 82(8):1495-500. PubMed ID: 9554526
[TBL] [Abstract][Full Text] [Related]
16. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
[TBL] [Abstract][Full Text] [Related]
18. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer.
Iwasaki T; Nakagawa K; Nakamura H; Takada Y; Matsui K; Kawahara K
Oncol Rep; 2005 Jun; 13(6):1075-80. PubMed ID: 15870924
[TBL] [Abstract][Full Text] [Related]
19. Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer.
Lin X; Gu J; Lu C; Spitz MR; Wu X
Clin Cancer Res; 2006 Oct; 12(19):5720-5. PubMed ID: 17020976
[TBL] [Abstract][Full Text] [Related]
20. Investigation of HER2 overexpression in non-small cell lung cancer.
Ugocsai K; Mándoky L; Tiszlavicz L; Molnár J
Anticancer Res; 2005; 25(4):3061-6. PubMed ID: 16080566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
